, Churchill Hospital, Oxford; Western General Hospital, Edinburgh; St Michael's Hospital, Bristol; Belfast City Hospital, Nottingham University Hospitals NHS Trust

, University Hospital of Wales, Cardiff; Alder Hey Hospital

. Kennedy-galton-centre, Harrow; Trinity College Dublin and St James's Hospital, Dublin, University Hospitals of Leicester NHS Trust

, Glan Clwyd Hospital, Rhyl; and Singleton Hospital, Swansea. We also wish to thank Steve Ellis

, Emmanuel Breysse who contributed by centralising, managing the data, and organising BRCA1 and BRCA2 mutation carriers follow-up and the Collaborating Centers which contributed to the mutation carriers recruitment and follow-up, BCFR thanks the members and participants in the Breast Cancer Family Registry from the

M. Gauthier-villars, M. D. , I. Curie, P. Buecher, M. D. et al.,

E. Luporsi, M. D. Phd, H. Metz-thionville, . De-mercy, F. Metz et al.,

M. Longy, . Phd, . Md-institut, and . Bergonié,

C. Dugast, ?. , M. D. Centre-eugène-marquis, R. Colas, . Md et al.,

A. Lortholary, C. Md, C. Paul-papin, . De-sienne, . Angers et al.,

I. Tennevet, . Md, H. Centre, R. Becquerel, M. D. Limacher et al.,

L. Demange, ?. , M. D. , P. Courlancy, R. Penet et al.,

H. Zattara-cannoni, M. D. , and H. De-la-timone,

S. Fert-ferrer, M. D. , H. Dieu--centre, C. ;. Hospitalier, O. Bera et al., Fort de France. ? Deceased. HCSC acknowledge the staff for their technical assistance. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Netherlands Cancer Institute (coordinating centre), Erasmus Medical Center

, NL: H.E.J. Meijers-Heijboer

M. J. Blok;-university-of-groningen and N. C. Oosterwijk, We thank Heather Thorne, Eveline Niedermayr and all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the many families who contribute to kConFab for their contributions to this resource. Czech Republic, MMCI, Brno-for the data collection and management. We wish to thank the Hungarian Breast and Ovarian Cancer Study Group members; the Department of Molecular Genetics

, Wendy Chung reports potential conflict of interest from Regeneron and Biogen

, Olivier Caron from AstraZeneca and IPSEN

P. Pujol, G. Astrazeneca, . Health, and . Roche,

. D-gareth-evans, AstraZeneca and AmGen

D. Eccles, P. Fabre, . Astrazeneca;-karin, R. Kast, A. ;. Pharma et al., University of Utah Foundation and Ambry Genetics. Anne-Marie Gerdes participated in an Advisory Board Meeting London in 2016, sponsored by Astra Zeneca about BRCA-testing in ovarian cancer

, Box 90203, 1006 BE Amsterdam, The Netherlands. 3 Department of Medical Oncology, Oncogénétique Clinique, Institut Paoli-Calmettes, vol.4, issue.8

C. Genetics, &. Guy, and S. Thomas, NHS Foundation Trust

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst, vol.105, issue.11, pp.812-834, 2013.

K. B. Kuchenbaecker, J. L. Hopper, D. R. Barnes, K. A. Phillips, T. M. Mooij et al., Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, JAMA, vol.317, issue.23, pp.2402-2418, 2017.

N. D. Kauff, S. M. Domchek, T. M. Friebel, M. E. Robson, J. Lee et al., Riskreducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study, J Clin Oncol, vol.26, issue.8, pp.1331-1338, 2008.

T. R. Rebbeck, N. D. Kauff, and S. M. Domchek, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst, vol.101, issue.2, pp.80-87, 2009.

A. Eisen, J. Lubinski, J. Klijn, P. Moller, H. T. Lynch et al., Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study, J Clin Oncol, vol.23, issue.30, pp.7491-7497, 2005.

S. M. Domchek, T. M. Friebel, C. F. Singer, D. G. Evans, H. T. Lynch et al., Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA, vol.304, issue.9, pp.967-75, 2010.

H. M. Klaren, L. J. Van't-veer, F. E. Van-leeuwen, and M. A. Rookus, Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation, J Natl Cancer Inst, vol.95, issue.13, pp.941-948, 2003.

I. E. Fakkert, M. J. Mourits, L. Jansen, D. M. Van-der-kolk, K. Meijer et al., Breast cancer incidence after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers, Cancer Prev Res, vol.5, issue.11, pp.1291-1298, 2012.

B. A. Heemskerk-gerritsen, C. Seynaeve, C. J. Van-asperen, M. G. Ausems, J. M. Collee et al., Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst, vol.107, issue.5, 2015.

B. A. Heemskerk-gerritsen, M. J. Hooning, M. A. Rookus, and . Response, J Natl Cancer Inst, vol.107, issue.9, 2015.

K. A. Phillips, P. N. Butow, A. E. Stewart, J. H. Chang, P. C. Weideman et al., Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort, Familial Cancer, vol.4, issue.2, pp.105-118, 2005.

H. Thorne, G. Mitchell, and S. Fox, kConFab: a familial breast cancer consortium facilitating research and translational oncology, J Natl Cancer Inst Monogr, vol.43, pp.79-81, 2011.

D. Goldgar, C. Bonnardel, and H. Renard, The international BRCA1/2 carrier cohort study: purpose, rationale, and study design, Breast Cancer Res, vol.2, issue.10, 2000.

E. M. John, J. L. Hopper, J. C. Beck, J. A. Knight, S. L. Neuhausen et al., The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer, Breast Cancer Res, vol.6, issue.4, pp.375-89, 2004.

M. B. Terry, K. A. Phillips, M. B. Daly, E. M. John, I. L. Andrulis et al., Cohort profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC), Int J Epidemiol, vol.45, issue.3, pp.683-92, 2016.

J. Kotsopoulos, T. Huzarski, J. Gronwald, C. Kim-sing, S. Neuhausen et al., Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst, vol.109, issue.1, 2017.

T. R. Rebbeck, T. Friebel, T. Wagner, H. T. Lynch, J. E. Garber et al., Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group, J Clin Oncol, vol.23, issue.31, pp.7804-7814, 2005.

J. Kotsopoulos, J. Gronwald, B. Y. Karlan, T. Huzarski, N. Tung et al., Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers, JAMA Oncol, vol.4, issue.8, pp.1059-65, 2018.

M. B. Terry, M. B. Daly, K. A. Phillips, X. Ma, N. Zeinomar et al., Riskreducing oophorectomy and breast cancer risk across the spectrum of familial risk, J Natl Cancer Inst, 2018.

F. R. Day, K. S. Ruth, D. J. Thompson, K. L. Lunetta, N. Pervjakova et al., Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair, Nat Genet, vol.47, issue.11, pp.1294-303, 2015.

I. M. Collins, R. L. Milne, S. A. Mclachlan, M. Friedlander, M. Hickey et al., Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, J Clin Oncol, vol.31, issue.31, pp.3920-3925, 2013.

K. Oktay, J. Y. Kim, D. Barad, and S. N. Babayev, Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks, J Clin Oncol, vol.28, issue.2, pp.240-244, 2010.

A. Finch, A. Valentini, E. Greenblatt, H. T. Lynch, P. Ghadirian et al., Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation, Fertil Steril, vol.99, issue.6, pp.1724-1732, 2013.

T. C. Van-tilborg, F. J. Broekmans, A. Pijpe, L. H. Schrijver, T. M. Mooij et al., Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?, Menopause, vol.23, issue.8, pp.903-913, 2016.

K. A. Phillips, I. M. Collins, R. L. Milne, S. A. Mclachlan, M. Friedlander et al., Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations, Hum Reprod, vol.31, issue.5, pp.1126-1158, 2016.

, Menarche, menopause, and breast cancer risk: individual participant metaanalysis, including 118 964 women with breast cancer from 117 epidemiological studies, Lancet Oncol, vol.13, issue.11, pp.1141-1151, 2012.

, National Comprehensive Cancer Network (NCCN) clinical practice guidelines in Oncology, 2019.

, Cancer Australia clinical recommendations for management of women at high risk of ovarian cancer, 2019.

S. M. Domchek, T. M. Friebel, S. L. Neuhausen, T. Wagner, G. Evans et al., Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, Lancet Oncol, vol.7, issue.3, pp.223-232, 2006.

K. Metcalfe, H. T. Lynch, W. D. Foulkes, N. Tung, C. Kim-sing et al., Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers, JAMA Oncol, vol.1, issue.3, pp.306-319, 2015.

T. Huzarski, T. Byrski, J. Gronwald, C. Cybulski, O. Oszurek et al., The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, vol.156, issue.2, pp.371-379, 2016.

V. M. Van-verschuer, B. A. Heemskerk-gerritsen, C. H. Van-deurzen, I. M. Obdeijn, M. M. Tilanus-linthorst et al., Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingooophorectomy, Cancer Biol Ther, vol.15, issue.4, pp.371-380, 2014.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations